Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZYMOQ
ADC Name
Rituximab-Compound (XLI)
Synonyms
Rituximab Compound (XLI)
   Click to Show/Hide
Organization
Orum Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Burkitt lymphoma [ICD11:2A85]
Investigative
Drug-to-Antibody Ratio
1-2
Structure
Antibody Name
Rituximab
  Antibody Info 
Antigen Name
B-lymphocyte antigen CD20 (MS4A1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Rituximab-Compound (XLI) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
> 2
nM
BT-474 cells
Invasive breast carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 2.00 nM High HER2 expression (HER2+++)
Method Description
The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
References
Ref 1 Linkers for use in antibody drug conjugates; 2023-03-16.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.